WC
TVRD

Wexford Capital’s Tvardi Therapeutics TVRD Stock Holding History

Wexford Capital’s Portfolio TVRD Stock Details TVRD Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q1 		– Sell
-475
Closed -$12.7K – 292
2023
Q4 		$12.7K Buy
+475
New +$19.7K ﹤0.01% 214
2015
Q3 		– Sell
-1,389
Closed -$608K – 102
2015
Q2 		$608K Buy
+1,389
New +$537K 0.16% 52

Other funds holding TVRD

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
DGI
Disciplined Growth Investors Minneapolis, Minnesota $4.89B AUM 33.85% 1-Year Est. Return
C
Chescapmanager Baltimore, Maryland $1.12B AUM 67.49% 1-Year Est. Return
FCM
Farallon Capital Management San Francisco, California $17.5B AUM 50.95% 1-Year Est. Return
RA
Rosalind Advisors Toronto, Ontario, Canada $249M AUM 80.12% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Stifel Financial
Stifel Financial St. Louis, Missouri $109B AUM 21.36% 1-Year Est. Return

Wexford Capital's TVRD Position: Q1 2024 in Review

Wexford Capital sold out of Tvardi Therapeutics (TVRD) in Q1 2024, closing a stake of 475 shares — an estimated $12.7K sold.

Wexford Capital first reported a position in TVRD in Q2 2015 and held it in 2 quarters. The position peaked at $608K in Q2 2015. 97 funds tracked by Wall St. Rank hold TVRD as of Q1 2024.

  • Wexford Capital reported no remaining Tvardi Therapeutics position as of Q1 2024 after selling out during the quarter.
  • Wexford Capital sold 475 Tvardi Therapeutics shares in Q1 2024, an estimated $12.7K.
  • Wexford Capital first reported a position in Tvardi Therapeutics in Q2 2015 and held it in 2 quarters.
  • Wexford Capital's Tvardi Therapeutics position peaked at $608K in Q2 2015.
  • 97 funds tracked by Wall St. Rank held Tvardi Therapeutics as of Q1 2024.

Based on Wexford Capital's 13F filing for Q1 2024, filed 15 May 2024.